Alibaba bans online listing and trade of pharmaceutical products
Sweeping ban includes APIs, intermediates and prescription and OTC medicines and comes amid tight regulatory requirements and the "high risk nature" of pharma products, e-commerce giant says
Chinese e-commerce platform Alibaba has prohibited the listing and trading of pharmaceutical products, including active pharmaceutical ingredients (APIs), intermediates and prescription and over-the-counter medicines.
The sweeping ban came into effect on Wednesday, April 28, after initially being announced on April 20 with Alibaba saying that penalties will start to be imposed against any violations of the new rules.
The largely unexpected move will hand competitive advantage to regulated and specialized online operators such as Kemiex, Amazon Pharmacy and others in their respective fields.
“In light of the regulatory requirements and the high risk nature of pharmaceutical products, Alibaba.com has revised the ‘Rules of Prohibited and Restricted Products’ to assist members in complying with applicable laws and maintain the sustainable development of the platform,” the company said in a notice to clients.
As a result, Alibaba said it would be shutting down four sub-categories on its platform (Medicine, Pharmaceutical, Veterinary Medicine and Herbal Medicine) and products listed under these headings would be “taken down in batches” and banned from being sold under any other categories.
Pharma products subject to the ban also include human and animal drugs, hormonal drugs, steroids, radiopharmaceuticals, antibiotics, vaccines, traditional Chinese herbs and medicines and special pharmaceuticals such as analeptics and blood products.
“The aforementioned products are strictly prohibited by the platform, regardless of whether the seller, the buyer, the manufacturer or the product has relevant qualifications,” Alibaba said, adding that non-compliant products will be removed from listing or deleted.
“Kemiex remains the only regulated online platform to buy and sell pharmaceutical raw materials,” said Pau Franquet, chief executive officer at the online trade platform and data provider, adding that the company holds a Good Distribution Practice (GDP) certification from Swissmedic.
Seen as a worldwide pioneer, Switzerland strengthened its regulatory landscape and Therapeutic Products Act in 2019 in anticipation of a growing ecosystem of online solutions, as well as explicitly recognizing broker and agency activities.
The global online pharmacy market – which delivers finished prescription and OTC products – continues to grow due to increasing internet access and the popularity of smartphones, with dominant players including Amazon, Carepoint Healthcare and Giant Eagle.
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance